checkAd

    DGAP-News  327  0 Kommentare Geratherm Medical AG: The international medical journal ´Stroke´ published convincing results of a clinical trial conducted at the University Hospital Heidelberg, Germany - Seite 3


    prevention (SRAdoc und SRA24), which is offered to General practitioners.

    Supplementary information about apoplex medical technologies
    apoplex medical technologies GmbH was founded in 2004 in Pirmasens, in the
    west of the Rhineland-Palatinate, and, within the field of medical
    technology, specializes in new and innovative technological products for
    the prevention of strokes throughout the world. The subsidiary of Geratherm
    Medical AG focuses on easily applicable and efficient methods of patient
    screening using medical-technical applications to prevent strokes and
    vascular dementia. The SRA (Stroke Risk Analysis) procedure is the first
    practicable screening method for paroxysmal atrial fibrillation. It is
    available in versions for use in medical practices and stroke units.
    apoplex medical technologies is supported by an extensive academic and
    clinical network, which professionally supplements its own core competences
    in the fields of mathematics, physics and medicine. Further information is
    available at www.apoplexmedical.com.

    Additional information     
    apoplex medical technologies GmbH   
    Albert Hirtz       
    Delaware Avenue 1 - 3     
    D-66953 Pirmasens      
    fon: +49/(0)6331/698998-0     
    fax: +49/(0)6331/698998-19     
    http://www.apoplexmedical.com      
    a.hirtz@apoplexmedical.com     

    End of Corporate News




    08.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a
    company of EquityStory AG.
    The issuer is solely responsible for the content of this announcement.

    DGAP´s Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de




    Language:    English                                               
    Company:     Geratherm Medical AG                                  
                 Fahrenheitstraße 1                                    
                 98716 Geschwenda                                      
                 Germany                                               
    Phone:       +49 (0)36205 98-0                                     
    Fax:         +49 (0)36205 98-1 15                                  
    E-mail:      info@geratherm.com                                    
    Internet:    www.geratherm.com                                     
    ISIN:        DE0005495626                                          
    WKN:         549562                                                
    Listed:      Regulierter Markt in Frankfurt (Prime Standard);      
                 Freiverkehr in Berlin, Düsseldorf, Hamburg, München,   
                 Stuttgart                                             

    End of News    DGAP News-Service  

      
    180850 08.08.2012                                                      
    Seite 3 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Geratherm Medical AG: The international medical journal ´Stroke´ published convincing results of a clinical trial conducted at the University Hospital Heidelberg, Germany - Seite 3 DGAP-News: Geratherm Medical AG / Key word(s): StudyGeratherm Medical AG: The international medical journal ´Stroke´published convincing results of a clinical trial conducted at theUniversity Hospital Heidelberg, Germany08.08.2012 / 10:11Clinical …